Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy

#1228

Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.

Aim(s): Assess efficacy of a multi analyte algorithmic (MAAA) blood gene transcript test and CgA in defining PRRT efficacy.

Materials and methods: NETs (n=32), M: F 22:10, median age 67, bronchial: n=8, GEP-NET: n=22, CUP: n=2 were evaluated. 19/32 were G1/G2, 19/29 were FDG+ve and 24/32 had progressive disease (PD). Status was assessed clinically and with imaging (RECIST). Cumulative Lu-PRRT activity was 4.6-27.8 GBq, median 18.5. Transcript analysis was by qRT-PCR and ELISA for CgA (EuroDiagnostica). The MAAA NETest mathematically delineates disease activity risk: scale 0-100%; minimal <20%, low: 20-47%, high >47%.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Bodei L

Authors: Bodei L, Paganelli G, Kidd M, Severi S, Lepensky C,

Keywords: Gene transcripts, NETest, neuroendocrine, PRRT,